Afinitor is a brand-name drug that’s prescribed for certain seizures, cancers, and tumors. Afinitor contains the active ingredient everolimus and may not be safe to take during pregnancy and ...

Afinitor (everolimus) is a prescription drug that’s used to treat some types of cancer, seizures, and certain tumors. This drug can interact with other medications and some supplements.

Patients with previously treated advanced clear cell renal cell carcinoma (RCC) — a type of kidney cancer — experienced improvements in progression and response via treatment with Welireg (belzutifan) ...

NHS England has reversed a previous decision and will be funding Novartis’ Afinitor (everolimus) for TSC-related refractory epilepsy from April 2019. The new decision means that Afinitor will be ...

While Welireg (belzutifan) has outperformed Afinitor (everolimus) in OS at 12 months and 24 months, the results have not achieved statistical significance. The OS gap between Welireg and Afinitor ...

Afinitor (everolimus) has been approved in the EU for advanced, progressive, non-functional neuroendocrine tumours (NETs) of gastrointestinal and lung origin and is the first oral therapy for this ...

Belzutifan improved progression-free survival and objective response rate compared to everolimus in previously treated ...

An expert provides answers to readers’ questions regarding different aspects of the kidney cancer experience, such as protein intake and clinical trials.

Synthetic derivatives of rapamycin have now been approved or are being investigated as therapeutics in cancer (Torisel, temsirolimus; Afinitor, everolimus; ridaforolimus) and in other diseases.

However, bucking that trend is Novartis, which had three approvals — Afinitor [everolimus, for the treatment of renal cell carcinoma], Coartem [artemether and lumefantrine, for the treatment of ...

Cancer growth blockers are also called cancer growth inhibitors. They are a type of targeted cancer drug. Our body makes chemicals called growth factors that control cell growth. Cancer growth ...

We have summarized in this article the current state of combination therapy of approved targeted drugs and irradiation. Since the introduction of the first targeted compounds almost (trastuzumab ...